RhumbLine Advisers
TERN

RhumbLine Advisers’s Terns Pharmaceuticals TERN Stock Holding History

RhumbLine Advisers’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.5M Buy
123,334
+17,093
+16% +$702K 0.01% 1269
2025
Q4 		$4.29M Buy
106,241
+1,404
+1% +$32.4K ﹤0.01% 1471
2025
Q3 		$787K Sell
104,837
-1,614
-2% -$10.3K ﹤0.01% 2389
2025
Q2 		$397K Buy
106,451
+9,792
+10% +$30.6K ﹤0.01% 2827
2025
Q1 		$267K Sell
96,659
-1,233
-1% -$5.04K ﹤0.01% 2955
2024
Q4 		$542K Buy
97,892
+13,479
+16% +$91.3K ﹤0.01% 2636
2024
Q3 		$704K Sell
84,413
-4,228
-5% -$34.8K ﹤0.01% 2474
2024
Q2 		$604K Buy
88,641
+29,659
+50% +$180K ﹤0.01% 2539
2024
Q1 		$387K Buy
58,982
+1,419
+2% +$9.27K ﹤0.01% 2816
2023
Q4 		$374K Sell
57,563
-1,566
-3% -$8.28K ﹤0.01% 2832
2023
Q3 		$297K Buy
59,129
+1,179
+2% +$7.48K ﹤0.01% 2941
2023
Q2 		$507K Buy
+57,950
New +$675K ﹤0.01% 2675

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

RhumbLine Advisers's TERN Position: Q1 2026 in Review

RhumbLine Advisers increased its Terns Pharmaceuticals (TERN) stake by 16% in Q1 2026, buying an estimated $702K and bringing the position to 123,334 shares worth $6.5M. The position accounts for 0.01% of the portfolio, ranked #1269.

RhumbLine Advisers first reported a position in TERN in Q2 2023 and has held it in 12 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • RhumbLine Advisers held 123,334 shares of Terns Pharmaceuticals worth $6.5M as of Q1 2026.
  • RhumbLine Advisers bought 17,093 Terns Pharmaceuticals shares in Q1 2026, an estimated $702K.
  • Terns Pharmaceuticals made up 0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #1269 holding.
  • RhumbLine Advisers first reported a position in Terns Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.